TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17953333

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neostigmine plus atropine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 60
Study: 15476756

Group type: EXPERIMENTAL
Intervention: Stage-Matched Intervention (SMI) for 3 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual educational advice
Number of subjects: 45
Study: 10665129

Group type: EXPERIMENTAL
Intervention: 40 micrograms ipratropium bromide plus 2 puffs placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol fumarate plus 3 puffs placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 80 micrograms ipratropium
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 24 micrograms formoterol plus 2 puffs placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol plus 40 micrograms ipratropium plus 1 puff placebo
Number of subjects: 27

Group type: COMPARATOR
Intervention: 4 puffs placebo
Number of subjects: 27
Study: 8922243

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy and limited field irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Staging laparotomy and splenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined chemotherapy and RT
Number of subjects: 0
Study: 1919695

Group type: EXPERIMENTAL
Intervention: Hyperventilation (PaCO2 25 +/- 2 mm Hg)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Hyperventilation plus THAM (PaCO2 25 +/- 2 mm Hg)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Normal ventilation (PaCO2 35 +/- 2 mm Hg)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (Normal ventilation)
Number of subjects: 113
Study: 6354209

Group type: EXPERIMENTAL
Intervention: 250 mg tolbutamide injected i.v. every four hours
Number of subjects: 4
Study: 31068943

Group type: EXPERIMENTAL
Intervention: miR-155-5p expression pre-transplantation
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: miR-181a-5p expression pre-transplantation
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: miR-181a-5p, miR-155-5p, and miR-122-5p expression post-transplantation
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: miR-181a-5p expression post-transplantation
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Combination of miR-181a-5p and miR-155-5p expression post-transplantation
Number of subjects: 145
Study: 29463278

Group type: EXPERIMENTAL
Intervention: medialized bilateral screw pedicel fixation (mPACT)
Number of subjects: 154

Group type: COMPARATOR
Intervention: traditional trajectory for lumbar pedicle screw placement
Number of subjects: 154
Study: 26367500

Group type: EXPERIMENTAL
Intervention: CYP2D6*5
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: CYP2D6*14
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: SLCO1B1 rs4149056
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: ABCG2 rs2231142
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: CYP2D6*41
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: SLCO1B1 rs4149015
Number of subjects: 133
Study: 23194256

Group type: EXPERIMENTAL
Intervention: Technology-supported behavioral weight loss (TECH)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard behavioral weight loss (STND)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Self-guided behavioral weight loss (SELF)
Number of subjects: 96
Study: 20193974

Group type: EXPERIMENTAL
Intervention: Diabetes patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 25
Study: 18580589

Group type: EXPERIMENTAL
Intervention: Panax ginseng powder (4.5 g/d) for 12 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no ginseng treatment)
Number of subjects: 97
Study: 15778567

Group type: EXPERIMENTAL
Intervention: Empowerment Program
Number of subjects: 0
Study: 12376221

Group type: EXPERIMENTAL
Intervention: Intravesicle 4% formalin instillation (Group I)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Endoscopic placement of 10% formalin-soaked pledgets (Group II)
Number of subjects: 19
Study: 10325267

Group type: EXPERIMENTAL
Intervention: Hysteroscopic scissors with a specially designed uterine balloon catheter
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Microlaparoscopy scissors with a cervical cannula
Number of subjects: 14
Study: 8757031

Group type: EXPERIMENTAL
Intervention: Cervical magnetic stimulation with a butterfly-shaped magnetic coil at 1-cm intervals, constant output, and random order.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cervical magnetic stimulation with a butterfly-shaped magnetic coil.
Number of subjects: 6
Study: 1673051

Group type: EXPERIMENTAL
Intervention: Buflomedil
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 6837492

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg zinc added to vitamin and mineral supplements)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (similar vitamin and mineral supplements without added zinc)
Number of subjects: 213
Study: 30952500

Group type: EXPERIMENTAL
Intervention: Quadrivalent meningococcal conjugate vaccine (MCV)
Number of subjects: 50
Study: 29734571

Group type: EXPERIMENTAL
Intervention: Closed-circuit rebreather (CCR) dive (PO₂ 1.4)
Number of subjects: 6

Group type: COMPARATOR
Intervention: CTRL (breathing air)
Number of subjects: 6
Study: 27081191

Group type: EXPERIMENTAL
Intervention: Dexcom G4 continuous glucose monitoring (CGM)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Dexcom G4 CGM
Number of subjects: 161
Study: 24498023

Group type: EXPERIMENTAL
Intervention: Bromocriptine (dopaminergic agonist)
Number of subjects: 0
Study: 22188747

Group type: EXPERIMENTAL
Intervention: Topical capsaicin (200 μl, 5%)
Number of subjects: 22
Study: 20171421

Group type: EXPERIMENTAL
Intervention: Test formulation of clopidogrel 75-mg tablets
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of clopidogrel 75-mg tablets
Number of subjects: 24
Study: 18065851

Group type: EXPERIMENTAL
Intervention: Telephone-based counseling sessions (up to 6 sessions at 6-month intervals over 24 months)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Telephone-based counseling sessions
Number of subjects: 231
Study: 17763408

Group type: EXPERIMENTAL
Intervention: Continuous-sequential estrogen-progestogen regimen (n = 52)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (n = 54)
Number of subjects: 106
Study: 15370796

Group type: EXPERIMENTAL
Intervention: Intervention group (3500 patients)
Number of subjects: 8135

Group type: COMPARATOR
Intervention: Control group (4635 patients)
Number of subjects: 8135
Study: 11118919

Group type: EXPERIMENTAL
Intervention: SonoVue (Bracco) 0.3 ml
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: SonoVue (Bracco) 0.6 ml
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: SonoVue (Bracco) 1.2 ml
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: SonoVue (Bracco) 2.4 ml
Number of subjects: 220
Study: 9096977

Group type: EXPERIMENTAL
Intervention: Diet only
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Exercise only
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Diet plus exercise
Number of subjects: 577

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 577
Study: 1345034

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 38
Study: 4048837

Group type: EXPERIMENTAL
Intervention: Gastroduodenostomy (BI)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Roux-en-Y diversion
Number of subjects: 27
Study: 31818310

Group type: EXPERIMENTAL
Intervention: Psychosomatic therapy in addition to usual care
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 158
Study: 30264849

Group type: EXPERIMENTAL
Intervention: Exercises with a pelvic realignment device (group R, n=25)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Stabilization exercise (group E, n=25)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (group C, n=25)
Number of subjects: 75
Study: 27066903

Group type: EXPERIMENTAL
Intervention: Perceval S valve implantation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional stented biological prosthesis (Soprano LivaNova)
Number of subjects: 25
Study: 24247740

Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 21565432

Group type: EXPERIMENTAL
Intervention: Telephone assessment
Number of subjects: 380

Group type: COMPARATOR
Intervention: Direct contact assessment
Number of subjects: 380
Study: 20158899

Group type: EXPERIMENTAL
Intervention: Existing search strategy (randomized controlled trial.pt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined search strategy with cluster design-related terms using AND
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined search strategy with Boolean operator OR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual inspection of full-text articles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of CRT identification over time
Number of subjects: 0
Study: 17705082

Group type: EXPERIMENTAL
Intervention: Radially expanding trocars
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional cutting trocars
Number of subjects: 80
Study: 15740818

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care
Number of subjects: 204
Study: 11927522

Group type: EXPERIMENTAL
Intervention: clarithromycin
Number of subjects: 148

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 148
Study: 9445236

Group type: EXPERIMENTAL
Intervention: Experimental bandage heated to 38 degrees C for 1 week
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard gauze bandage (control) applied to contralateral thigh
Number of subjects: 18
Study: 8583233

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: MS patients
Number of subjects: 13

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 13
Study: 2653742

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 6928

Group type: EXPERIMENTAL
Intervention: Dibenzepin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study: 31711219

Group type: EXPERIMENTAL
Intervention: Intervention with practice facilitators trained in improving practice-level BP control over 12 months (13 visits).
Number of subjects: 257
Study: 29243519

Group type: EXPERIMENTAL
Intervention: Multilevel intervention
Number of subjects: 536
Study: 29130588

Group type: EXPERIMENTAL
Intervention: HT042
Number of subjects: 129
Study: 27836873

Group type: EXPERIMENTAL
Intervention: GoActive intervention
Number of subjects: 460

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 460
Study: 25246162

Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in elderly subjects
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in elderly males
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in elderly females
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in non-elderly subjects
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem tartrate tablet (ZST) 1.75 mg and 3.5 mg in elderly subjects
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem tartrate tablet (ZST)
Number of subjects: 46
Study: 21760473

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enalapril 10 mg once daily
Number of subjects: 20
Study: 19641358

Group type: EXPERIMENTAL
Intervention: Alfuzosin XL 10 mg once daily for 2 days
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 17726350

Group type: EXPERIMENTAL
Intervention: Operative and pharmaceutical approaches for treatment of infection stones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metaphylactic treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnosis through urinalysis and urine culture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaging techniques
Number of subjects: 0
Study: 15894896

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 420

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 420
Study: 12755527

Group type: EXPERIMENTAL
Intervention: Two doses of recombinant Hepatitis B vaccine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Three doses of recombinant Hepatitis B vaccine
Number of subjects: 99
Study: 10338107

Group type: EXPERIMENTAL
Intervention: Piracetam 4.8g daily for 12 weeks
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: Piracetam 12g intravenous bolus, 12g daily for 4 weeks, and 4.8g daily for a further 8 weeks
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: Piracetam treatment within 7 hours of stroke onset
Number of subjects: 927

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study: 8739658

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 144

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 144
Study: 1928712

Group type: EXPERIMENTAL
Intervention: rHuEPO (200 IU/kg subcutaneously, 7 times starting 3 days after first blood withdrawal)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no rHuEPO treatment)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study: 6804625

Group type: EXPERIMENTAL
Intervention: CO2 inhalation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Air (placebo)
Number of subjects: 0
Study: 30694978

Group type: EXPERIMENTAL
Intervention: Lower-intensity PA (300 min·wk at 40%-59% of HR reserve)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Higher-intensity PA (150 min·wk at 60%-80% of HR reserve)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no PA intervention)
Number of subjects: 45
Study: 30213052

Group type: EXPERIMENTAL
Intervention: Half-A (68 g fresh Hass avocado)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Whole-A (136 g fresh Hass avocado)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (0 g avocado)
Number of subjects: 31
Study: 26795936

Group type: EXPERIMENTAL
Intervention: 10-week, Internet-based, cognitive-behavioral intervention
Number of subjects: 206

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 206
Study: 25179979

Group type: EXPERIMENTAL
Intervention: Totally thoracoscopic surgery
Number of subjects: 254
Study: 22323869

Group type: EXPERIMENTAL
Intervention: Oral solubilized UDCA (3.5 g/140 mL/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 20661198

Group type: EXPERIMENTAL
Intervention: 5% human albumin (HA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (HES)
Number of subjects: 36
Study: 18179342

Group type: EXPERIMENTAL
Intervention: Informational lectures
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Brief, clinician-based approach
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 105
Study: 15857210

Group type: EXPERIMENTAL
Intervention: Ganopoly (polysaccharide extract of G. lucidum)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 12199869

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9475317

Group type: EXPERIMENTAL
Intervention: Chronic lung disease (CLD)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Respiratory distress syndrome (RDS)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control babies
Number of subjects: 47
Study: 7715468

Group type: EXPERIMENTAL
Intervention: Grapefruit juice intake
Number of subjects: 8

Group type: COMPARATOR
Intervention: No grapefruit juice intake (control)
Number of subjects: 8
Study: 3296876

Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 104

Group type: COMPARATOR
Intervention: Comparison of Lidocaine and Bupivacaine
Number of subjects: 104
Study: 30114980

Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy model in occupational rehabilitation programme
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Transdiagnostic approach
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Number of subjects: 22
Study: 30420682

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 26016834

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) program of moderate intensity (3 sessions/week on a bicycle at 60-70% VO2peak for 3 months, followed by one session/week until 1-year follow-up)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no formal ET)
Number of subjects: 51
Study: 24781718

Group type: EXPERIMENTAL
Intervention: SprayShield™ Adhesion Barrier
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no anti-adhesion treatment)
Number of subjects: 15
Study: 23097096

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg) administered intravenously in three doses, eight hours apart
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 19108988

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Perindopril/Indapamide
Number of subjects: 6105
Study: 17209672

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenofibrate plus statin
Number of subjects: 0
Study: 15164294

Group type: EXPERIMENTAL
Intervention: Tennis players with tournament experience
Number of subjects: 110

Group type: COMPARATOR
Intervention: Tennis players without tournament experience
Number of subjects: 110
Study: 11222469

Group type: EXPERIMENTAL
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 1220

Group type: COMPARATOR
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: CABG (Coronary Artery Bypass Grafting) among diabetic patients
Number of subjects: 1220

Group type: COMPARATOR
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty) among diabetic patients
Number of subjects: 1220
Study: 9556238

Group type: EXPERIMENTAL
Intervention: Parks hemorrhoidectomy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy
Number of subjects: 34
Study: 7528405

Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TUR-P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open prostatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transurethral incision of the prostate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Newer less invasive procedures
Number of subjects: 0
Study: 3415889

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 20 ml h‐1 (in saline)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 20
Study: 8498894

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 42224

Group type: EXPERIMENTAL
Intervention: mepindolol-sulfate (2 x 2.5 mg)
Number of subjects: 20
Study: 31787433

Group type: EXPERIMENTAL
Intervention: Heparin-coated (HC) circuits
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nonheparin phosphorylcholine-coated (PC) circuits
Number of subjects: 26
Study: 31445354

Group type: EXPERIMENTAL
Intervention: Necitumumab (800 mg) with nab-paclitaxel (100 mg/m2) and carboplatin (AUC 6 mg*min/mL) for 4 cycles, followed by necitumumab and nab-paclitaxel maintenance
Number of subjects: 54
Study: 29234057

Group type: EXPERIMENTAL
Intervention: Carnosine supplementation (2g daily for 12 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 25794457

Group type: EXPERIMENTAL
Intervention: BCG induction followed by one BCG instillation every 3 months for 3 years (maintenance arm)
Number of subjects: 397

Group type: COMPARATOR
Intervention: BCG induction alone (no-maintenance arm)
Number of subjects: 397
Study: 23401618

Group type: EXPERIMENTAL
Intervention: E2 administration during the last 7 days of GnRHant
Number of subjects: 14

Group type: COMPARATOR
Intervention: GnRHant
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: E2 administration
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Submaximal LBNP
Number of subjects: 14
Study: 20549247

Group type: EXPERIMENTAL
Intervention: 12-h method
Number of subjects: 90

Group type: COMPARATOR
Intervention: 6-h method
Number of subjects: 90
Study: 19483223

Group type: EXPERIMENTAL
Intervention: Skin adhesive
Number of subjects: 90

Group type: COMPARATOR
Intervention: Surgical staples
Number of subjects: 90
Study: 17182820

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise, 45 min/d, 5 d/wk for 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise intervention of 60 min/d, 6 d/wk for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fat dietary pattern for 8-12 years
Number of subjects: 0
Study: 15955900

Group type: EXPERIMENTAL
Intervention: Lapatinib (GW572016) administered once daily at doses ranging from 500 to 1,600 mg
Number of subjects: 67
Study: 11449341

Group type: EXPERIMENTAL
Intervention: Enoxaparin, 40 mg once daily for 6 to 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9249964

Group type: EXPERIMENTAL
Intervention: Functional use of 'blue' and 'yellow' groups assigned on the basis of a biological attribute
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Functional use of 'blue' and 'yellow' groups assigned on the basis of a random drawing
Number of subjects: 61

Group type: COMPARATOR
Intervention: No explicit groups (despite the presence of blue and yellow groups)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Higher levels of self-esteem
Number of subjects: 61